low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, biotech sector sentiment and risk appetite correlate with broader equity markets. Patient enrollment can be affected by healthcare system capacity during economic stress, but DMD is a severe progressive disease where treatment decisions are less discretionary.

Rising rates create significant headwinds through two channels: (1) Higher discount rates compress NPV of distant future cash flows, disproportionately impacting pre-revenue biotechs with 3-5+ year monetization timelines, and (2) Reduced risk appetite shifts capital away from speculative growth stocks toward safer yield alternatives. The company's 3.59x current ratio provides liquidity buffer, but future financing costs increase in higher rate environments.

growth/momentum - The 300% 3-month return and 52% 1-year return attract speculative biotech investors focused on binary clinical/regulatory catalysts rather than fundamental cash flow analysis. High volatility and pre-revenue status appeal to risk-tolerant growth investors, venture-style healthcare funds, and momentum traders riding clinical trial newsflow. Not suitable for value or income investors given negative margins and no dividend potential.